Want to see HK:1827 full AI Analyst Report?
Top Page
Miricor Enterprises Holdings Ltd
(1827)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$0.95
▲(0.00% Upside)
Action:Reiterated
Date:07/30/26
The score is driven primarily by improving financial quality—strong recent operating/free cash flow and meaningful deleveraging—offset by weak operating trends, including a sharp FY2026 revenue contraction and thin EBIT/net margins. Technicals further weigh on the score as the share price trades below all key moving averages, while valuation is supportive with a moderate P/E.
Positive Factors
Deleveraging
Meaningful deleveraging strengthens the capital base and reduces financial strain, giving the company greater flexibility to withstand operating volatility. Lower leverage can also support future investment and reduce the drag that debt obligations place on cash allocation and earnings resilience.
Negative Factors
Revenue Contraction
The sharp revenue decline signals weakening top-line momentum and makes the business more dependent on cost control to protect earnings. Continued contraction would reduce operating leverage, limit reinvestment capacity and make recent improvements in cash flow harder to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging
Meaningful deleveraging strengthens the capital base and reduces financial strain, giving the company greater flexibility to withstand operating volatility. Lower leverage can also support future investment and reduce the drag that debt obligations place on cash allocation and earnings resilience.
Read all positive factors
Miricor Enterprises Holdings Ltd (1827) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$360.00M
Dividend Yield0%
Average Volume (3M)25.33K
Price to Earnings (P/E)12.6
Beta (1Y)-0.17
Revenue Growth-10.11%
EPS Growth6.04%
CountryHK
Employees235
SectorConsumer Cyclical
Sector Strength84
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.04
Shares Outstanding400,000,000
10 Day Avg. Volume17,500
30 Day Avg. Volume25,333
Financial Highlights & Ratios
PEG Ratio5.54
Price to Book (P/B)2.38
Price to Sales (P/S)1.04
P/FCF Ratio5.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Miricor Enterprises Holdings Ltd Business Overview & Revenue Model
Company Description
Miricor Enterprises Holdings Limited, an investment holding company, provides non-surgical medical aesthetic, wellness beauty services, and skincare products in Hong Kong and Mainland China. It offers non-surgical medical aesthetic services, inclu...
Miricor Enterprises Holdings Ltd Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
71
Positive
Cash Flow
77
Positive
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 362.39M | 403.15M | 494.26M | 463.12M | 363.92M |
| Gross Profit | 155.25M | 211.13M | 225.37M | 238.23M | 209.54M |
| EBITDA | 84.55M | 106.36M | 86.62M | 70.34M | 94.02M |
| Net Income | 11.23M | 10.59M | -12.62M | -20.50M | 25.38M |
Balance Sheet | |||||
| Total Assets | 423.67M | 471.28M | 479.44M | 516.81M | 476.81M |
| Cash, Cash Equivalents and Short-Term Investments | 258.15M | 192.17M | 182.43M | 179.32M | 128.16M |
| Total Debt | 50.73M | 88.76M | 99.75M | 130.28M | 127.58M |
| Total Liabilities | 265.40M | 323.72M | 342.68M | 366.10M | 305.54M |
| Stockholders Equity | 158.27M | 147.56M | 136.76M | 150.71M | 171.27M |
Cash Flow | |||||
| Free Cash Flow | 68.14M | 112.07M | 58.24M | 72.67M | -67.61M |
| Operating Cash Flow | 74.45M | 114.02M | 84.45M | 99.45M | 44.03M |
| Investing Cash Flow | 32.42M | -30.95M | -59.00M | -37.84M | -97.51M |
| Financing Cash Flow | -45.18M | -50.03M | -55.59M | -21.92M | -28.73M |
Miricor Enterprises Holdings Ltd Technical Analysis
Positive
0.95
Price Trends
0.82
Positive
0.83
Positive
0.86
Positive
Market Momentum
0.03
Negative
61.05
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1827, the sentiment is Positive. The current price of 0.95 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.82, and above the 200-day MA of 0.86, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 61.05 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1827.
Miricor Enterprises Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.65B | 9.21 | 43.78% | 11.19% | -14.68% | -13.60% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
61 Neutral | HK$360.00M | 12.59 | 18.47% | 0.00% | -10.11% | 6.04% | |
57 Neutral | HK$1.82B | 50.35 | 6.47% | ― | 2.78% | -41.23% | |
56 Neutral | HK$6.03B | 14.13 | 6.50% | 20.98% | ― | ― | |
56 Neutral | HK$132.80M | -14.69 | -61.33% | 3.14% | -38.43% | -394.12% | |
50 Neutral | HK$70.55M | -39.00 | -0.93% | 6.43% | -2.31% | 66.07% |
* Consumer Cyclical Sector Average
HK:1827
Miricor Enterprises Holdings Ltd
0.90
-0.11
-10.89%
HK:1448
Fu Shou Yuan International Group
2.64
-0.26
-8.84%
HK:0919
Modern Healthcare Technology Holdings Limited
0.08
>-0.01
-5.81%
HK:1830
Perfect Medical Health Management Limited
1.30
-0.11
-7.93%
HK:8483
Max Sight Group Holdings Limited
0.19
0.08
75.45%
HK:2521
Shenghui Cleanness Group Holdings Limited
0.95
0.63
195.31%
Miricor Enterprises Holdings Ltd Corporate Events
Miricor Seeks Shareholders’ Approval for New Share Option Scheme and Service Provider Sublimit
Aug 28, 2026
Miricor Enterprises Holdings Ltd has called an extraordinary general meeting for 18 September 2026 in Hong Kong to seek shareholder approval to terminate its existing share option scheme adopted in 2016 and replace it with a new share option schem...
Miricor sets September AGM to approve dividend, board changes and share issue mandate
Jul 23, 2026
Miricor Enterprises Holdings Ltd has called its annual general meeting for 18 September 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements for the year ended 31 March 2026 and vote on a proposed final d...
Miricor Enterprises Declares Final Cash Dividend for FY2026
Jun 26, 2026
Miricor Enterprises Holdings Limited has declared a final ordinary cash dividend of HKD 0.10 per share for the financial year ended 31 March 2026, subject to shareholder approval on 18 September 2026. The dividend will be paid in Hong Kong dollars...
Miricor lifts profit and dividend despite revenue decline in FY2026
Jun 26, 2026
Miricor Enterprises Holdings reported revenue of HK$362.4 million for the year ended 31 March 2026, down 10.1% from the prior year, as the group faced softer demand and a more challenging operating environment in its beauty and wellness businesses...
Miricor Sets June 26 Board Meeting to Approve Annual Results and Consider Final Dividend
Jun 15, 2026
Miricor Enterprises Holdings Ltd has scheduled a board meeting for 26 June 2026 to approve the audited annual results for the year ended 31 March 2026 and to authorize their publication. The board will also consider whether to recommend a final di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.